Inflammation Ushers in Calcification

HomeCirculationVol. 116, No. 24Inflammation Ushers in Calcification Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBInflammation Ushers in CalcificationA Cycle of Damage and Protection? Catherine M. Shanahan Catherine M. ShanahanCatherine M. Shanahan From the Division of Cardiovascular Medicine, Kings College London, London, United Kingdom. Originally published11 Dec 2007https://doi.org/10.1161/CIRCULATIONAHA.107.749655Circulation. 2007;116:2782–2785The layman's term "hardening of the arteries" is synonymous with vascular disease and describes the ubiquitous calcification of the intima and media of the vessel wall that occurs in atherosclerosis and aging. Vascular calcification measured and quantified by electron beam computer tomography is a powerful predictor of myocardial infarction, vascular complications such as amputation, and all-cause mortality.1 Despite this fact, calcification has remained a neglected pathology, particularly in the field of atherosclerosis. This neglect is due in part to the controversy surrounding whether calcification is a bystander marker of disease load or acts to induce plaque rupture and thus increase the cardiovascular event rate; it is also due to the long-held belief that vascular calcification is an end-stage dystrophic process and therefore not amenable to manipulation. However, huge progress has been made over the last 10 years in elucidating the cell biological mechanisms underlying vascular calcification.Article p 2841Consensus now exists that calcification is a regulated process, orchestrated by vascular smooth muscle cells (VSMCs) and occurring stepwise in a manner analogous to physiological mineralization processes. In the normal vessel wall, VSMCs are protected from calcification by local and circulating proteins such as matrix Gla protein and fetuin-A that act as mineralization inhibitors. However, in response to insults, VSMCs may die by apoptosis and release apoptotic bodies or may be induced by signals and mechanisms that are still not well defined to release matrix vesicles.2 These small membrane-bound microparticles have the capacity to concentrate calcium and phosphate to allow crystal nucleation and thus act as the first nidus for mineralization. Concomitant with vesicle release, although the precise order and relationship between these 2 events remain unclear, VSMCs undergo an osteo/chondrocytic phenotypic transition and begin to express transcription factors normally associated with differentiated chondrocytes and osteoblasts such as Sox 9, Cbfa1/Runx2, and osterix that regulate the expression of a cascade of mineralization regulating proteins such as alkaline phosphatase, osteopontin, and osteocalcin. These proteins act to regulate mineralization by altering the dynamics of crystal growth or by altering the availability of calcium and phosphate ions in the local environment.3 Key unanswered questions remain about what these initial damage-inducing agents might be, what the time course and order/sequence of events leading to the first initiation of calcification and VSMC osteogenic change are, and whether calcification is a purely pathological response or represents a protective adaptive response in VSMCs and/or the vasculature.The study of Aikawa et al4 in this issue of Circulation goes part way to answering some of these key questions. Using multiple state-of-the-art imaging modalities, the authors have been able to describe the earliest events in the relationship between inflammation and calcification and have elegantly shown that macrophage infiltration and inflammation precede both the osteogenic conversion of VSMCs and the vesicle release associated with the generation of the first nidus of microcalcifications, providing evidence for the first time in vivo that, at least in atherosclerosis, inflammation is a potent initiator of calcification. Using apolipoprotein E knockout mice fed a high-fat diet as a model, Aikawa et al analyzed atherosclerotic lesions at a number of early and late time points with both in vivo imaging and histological and electron microscopy techniques. They showed that osteogenesis associates with inflammation in very early stages of atherosclerosis by visualizing OsteoSense750, a previously described bisphosphonate-based imaging agent that binds calcium and hydroxyapatite (HA) and can be excited at 750 nm.5 Macrophages were imaged in the same near-infrared fluorescent range using nanoparticles excitable at 680 nm. Both of these activities were found to be highly correlated; they evolved in close proximity, overlapped at border regions, and increased with plaque progression, suggesting an intimate relationship between them. Indeed, inflammation volume and calcification volume increased over time, concomitantly further confirming an interrelationship. Moreover, OsteoSense750 signals correlated with the osteogenic conversion of VSMCs measured in histological sections via alkaline phosphatase activity (an early marker of osteogenic activity) and with expression of other mineralization-regulating proteins such as Cbfa1/Runx 2 and osteocalcin. Finally, fluorescent-activated cell sorter analysis was used to confirm that the cells expressing the inducible osteogenic marker osteopontin were not monocytic in origin and therefore likely to be VSMCs. Additionally, what was highly informative was the use of electron microscopy to identify preclinical microcalcifications well before histological stains such as von Kossa could detect their presence. Importantly, electron microscopy showed that microcalcifications and HA nanocrystals colocalized with cholesterol crystals and were present in membrane-bound vesicles in the size range of apoptotic bodies and matrix vesicles. They concluded that infiltrating macrophages drawn to sites of lipid accumulation induce VSMC death and VSMC phenotypic transition to an osteogenic phenotype via cytokine release. This scenario was strengthened by their observations that macrophage-conditioned media could increase expression of alkaline phosphatase in VSMCs and concurs with previous in vitro studies demonstrating that lipids and inflammatory cytokines released by macrophages accelerate osteogenic differentiation and calcification.6–9The idea that inflammation was likely to be the initial event very early on in plaque development leading to calcification is supported by further experiments using the same model with the addition of statin treatment.4 Statins, via their capacity to inhibit inflammation, reduced the increase in osteogenic and inflammatory coactivities with plaque progression, and this correlated with a reduction in calcification. Thus, early treatment of inflammation can ameliorate the calcification response in the vessel wall. In addition to the animal experiments, Aikawa et al applied the same methods and technologies to human carotid endarterectomy specimens ex vivo. This analysis showed the same coassociations of inflammation with OsteoSense750 throughout the lesions. Although these analyses on human lesions did not allow an accurate time course as did the mouse studies, they lend strong support to the notion that the events in the mouse lesions are mirrored in human atherosclerosis in vivo.An additional aspect of the study by Aikawa et al was the analysis of inflammation and calcification in advanced plaques in the same apolipoprotein E knockout mouse model.4 Here, the results were very different. In contrast to the early plaque calcifications, in aged mice with more advanced plaques, calcification was spatially distinct from macrophage accumulation. The lack of association between these 2 factors in advanced plaques suggests perhaps that calcification is initiated by factors other than inflammation as plaques progress. Alternatively, it may reflect the possibility that once calcification is established, it has the propensity to progress by physicochemical processes, enhanced by the absence of mineralization inhibitors, the expression of which may be compromised by loss of or damage to the VSMCs that produce them. Alternatively, it may represent a continuation of active osteogenic processes by VSMCs. Indeed, Aikawa et al showed that areas of inflammation also were decreased in advanced calcified plaques, suggesting an interrelationship between inflammation and calcification, but this time a negative one. Thus, we are left with the intriguing possibility that calcification can dampen inflammation and is protective in a manner perhaps analogous to the calcific mummification of infections that occurs in other soft tissues. Thus, by ensuring their own survival and using calcification to seal off inflammation, VSMCs may be prolonging the lifetime integrity of the vessel wall. So, does any evidence exist that calcification is an adaptive/protective response? And is it possible that calcified deposits can act directly on inflammation?The rapid initiation of osteogenic gene expression patterns in VSMCs in response to insults is highly suggestive of an adaptive response aimed at regulating mineralization. The proteins upregulated by osteogenic VSMCs include matrix Gla protein (MGP) and other "bone"-specific proteins that dampen and control the mineralization process.10 In addition, matrix vesicle release from VSMCs was first described as a protective mechanism against calcium overload, able to rescue VSMCs from apoptotic cell death.2,11 Moreover, vesicles released by VSMCs are loaded with calcification inhibitors, including matrix Gla protein and fetuin-A, that act to minimize their capacity to initiate calcification and facilitate their rapid phagocytosis.2,12,13 Potentially, elevated extracellular calcium at sites of apoptosis induces VSMC vesicle release, and in the absence of inhibitors or phagocytosis, microcalcifications result, with these events preceding the osteogenic differentiation of VSMCs. Indeed, this may be a universal initiation mechanism for both medial and intimal calcification, and it would be interesting to determine whether the technologies used in the Aikawa et al study could be adapted to investigate this idea in animal models of medial calcification.However, other evidence argues against the notion of calcification as protective. Recent in vitro studies have shown that microcalcifications induce a proinflammatory response in macrophages, leading to a vicious cycle of macrophage infiltration, matrix breakdown, VSMC apoptosis, and plaque rupture.14,15 Interestingly, it was found that HA crystals of <2 μm induced the most proinflammatory response in macrophages, with larger particles being inert. However, these studies used naked HA, whereas in the vessel wall, HA is complexed with a number of protein components that may block inflammatory responses. Moreover, in the Aikawa et al study, calcification also colocalized with cathepsin K, an enzyme involved in bone reabsorption, suggesting that macrophages may respond differentially to HA in the vessel wall. Indeed, medial calcification occurs in the absence of macrophage infiltration, suggesting that in vivo not all calcification is proinflammatory and that this is an area that requires further investigation of the effects of calcified deposits on not only macrophages but also VSMCs.16Finally, clinical studies clearly show that not all calcifications in vivo are the same. Intravascular ultrasound has shown that spotty calcification within a plaque is more predictive of a cardiovascular event than plate-like heavy calcification.17 Using the knowledge obtained from the Aikawa et al study, it seems likely that these "spotty" areas represent inflammatory lesions and therefore are more likely to rupture. Plaques with advanced calcification are potentially more benign because they are no longer inflammatory. Because atherosclerosis is a progressive inflammatory disease, it is clear that as long as inflammatory stimuli are present, there will be continuous cycles of inflammation leading to macrophage infiltration and microcalcifications. If each inflammatory region is contained, potentially by macrocalcification, and the VSMC repair system is not overwhelmed, over a lifetime, this process will lead to calcified fibrous acellular plaques. If, however, inflammation is sustained, the plaque may become heavily calcified but will still be prone to rupture if an ongoing inflammatory process is present with associated loss of VSMCs (the Figure). Although this hypothesis is controversial, these plaques also may rupture as a result of debonding around microcalcifications or may be susceptible to increased hemodynamic stresses and therefore prone to mechanical rupture.18,19 We should also remember that, within an individual, plaques are heterogeneous, exhibiting a continuum of inflammation and calcification, with any inflamed plaque, calcified or not, vulnerable to rupture.20Download figureDownload PowerPointFigure. Mechanisms of atherosclerotic calcification and its role in plaque stability. In atherosclerosis, proinflammatory signals such as modified lipoproteins (red) promote macrophage infiltration into the vessel wall. Macrophages express proinflammatory cytokines that induce VSMC apoptosis and osteogenic differentiation. The calcium release associated with apoptotic cells also may induce VSMC vesicle release. In the absence of inhibitors and phagocytosis, apoptotic bodies and vesicles can form a nidus for calcification. Initial microcalcifications may be proinflammatory and induce further cycles of inflammation. If inflammation continues, as the plaque advances, it will induce further VSMC apoptosis, fibrous cap thinning, and eventually plaque rupture. However, if inflammation is reduced by either treatment with statins or potentially progression of the calcification process, VSMC apoptosis is limited, and the plaque may be stabilized until further inflammatory events are initiated. TNF indicates tumor necrosis factor.In summary, the Aikawa et al study has provided important insights into the earliest cell biological mechanisms of atherosclerotic calcification in vivo and highlighted key issues that remain controversial in the field of atherosclerosis and calcification. If these technologies could be modified for use in the clinic, inflammation and microcalcification may eventually become the keys to identifying the vulnerable patient and the vulnerable plaque.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Dr Shanahan is a British Heart Foundation Senior Fellow.DisclosuresNone.FootnotesCorrespondence to Catherine M. Shanahan, PhD, Cardiovascular Division, James Black Centre, Kings College London, 125 Coldharbour Ln, London SE5 9NU, UK. E-mail [email protected] References 1 Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25 253 patients. J Am Coll Cardiol. 2007; 49: 1860–1870.CrossrefMedlineGoogle Scholar2 Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004; 15: 2857–2867.CrossrefMedlineGoogle Scholar3 Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med. 2006; 260: 192–210.CrossrefMedlineGoogle Scholar4 Aikawa E, Nahrendorf M, Figueiredo J-L, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007; 116: 2841–2850.LinkGoogle Scholar5 Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007; 115: 377–386.LinkGoogle Scholar6 Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002; 91: 570–576.LinkGoogle Scholar7 Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000; 102: 2636–2642.CrossrefMedlineGoogle Scholar8 Tintut Y, Patel J, Territo M, Saini T, Parhami F, Demer LL. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002; 105: 650–655.CrossrefMedlineGoogle Scholar9 Shioi A, Katagi M, Okuno Y, Mori K, Jono S, Koyama H, Nishizawa Y. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res. 2002; 91: 9–16.LinkGoogle Scholar10 Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994; 93: 2393–2402.CrossrefMedlineGoogle Scholar11 Fleckenstein-Grun G, Frey M, Thimm F, Hofgartner W, Fleckenstein A. Calcium overload: an important cellular mechanism in hypertension and arteriosclerosis. Drugs. 1992; 44 (suppl 1): 23–30.CrossrefMedlineGoogle Scholar12 Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005; 16: 2920–2930.CrossrefMedlineGoogle Scholar13 Proudfoot D, Davies JD, Skepper JN, Weissberg PL, Shanahan CM. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation. 2002; 106: 3044–3050.LinkGoogle Scholar14 Nadra I, Boccaccini AR, Philippidis P, Whelan LC, McCarthy GM, Haskard DO, Landis RC. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis. March 8, 2007. DOI: 10.1016/j.atherosclerosis.2007.02.005. Available at: http://www.sciencedirect.com. Accessed October 30, 2007.Google Scholar15 Nadra I, Mason JC, Philippidis P, Florey O, Smythe CD, McCarthy GM, Landis RC, Haskard DO. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res. 2005; 96: 1248–1256.LinkGoogle Scholar16 Bostrom K. Proinflammatory vascular calcification. Circ Res. 2005; 96: 1219–1220.LinkGoogle Scholar17 Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, Nakamura Y, Yamashita H, Yamagishi H, Takeuchi K, Naruko T, Haze K, Becker AE, Yoshikawa J, Ueda M. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004; 110: 3424–3429.LinkGoogle Scholar18 Vengrenyuk Y, Carlier S, Xanthos S, Cardoso L, Ganatos P, Virmani R, Einav S, Gilchrist L, Weinbaum S. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci U S A. 2006; 103: 14678–14683.CrossrefMedlineGoogle Scholar19 Tang D, Yang C, Zheng J, Woodard PK, Saffitz JE, Sicard GA, Pilgram TK, Yuan C. Quantifying effects of plaque structure and material properties on stress distributions in human atherosclerotic plaques using 3D FSI models. J Biomech Eng. 2005; 127: 1185–1194.CrossrefMedlineGoogle Scholar20 Moselewski F, O'Donnell CJ, Achenbach S, Ferencik M, Massaro J, Nguyen A, Cury RC, Abbara S, Jang IK, Brady TJ, Hoffmann U. Calcium concentration of individual coronary calcified plaques as measured by multidetector row computed tomography. Circulation. 2005; 111: 3236–3241.LinkGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yang P, Zang G, Yan Y, Zhong W, Li B, Xu Y, Shao C, Wang Z, Pu J and Yuan W (2022) CD137-CD137L Aggravates Calcification of Vascular Smooth Muscle Cell and Vasculature of ApoE−/− Mice Via Rab7-Mediated Autophagy, Journal of Cardiovascular Translational Research, 10.1007/s12265-022-10272-7, 15:6, (1297-1314), Online publication date: 1-Dec-2022. Waring O, Skenteris N, Biessen E and Donners M (2021) Two-faced Janus: the dual role of macrophages in atherosclerotic calcification, Cardiovascular Research, 10.1093/cvr/cvab301, 118:13, (2768-2777), Online publication date: 21-Oct-2022. Qin Z, Cao M, Xi X, Zhang Y, Wang Z, Zhao S, Tian Y, Xu Q, Yu H, Tian J and Yu B (2022) Cholesterol crystals in non-culprit plaques of STEMI patients: A 3-vessel OCT study, International Journal of Cardiology, 10.1016/j.ijcard.2022.06.016, 364, (162-168), Online publication date: 1-Oct-2022. Ramphal S, Govender N, Singh S, Khaliq O and Naicker T (2022) Histopathological features in advanced abdominal pregnancies co-infected with SARS-CoV-2 and HIV-1 infections: A case evaluation, European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 10.1016/j.eurox.2022.100153, 15, (100153), Online publication date: 1-Aug-2022. Rudloff S, Jahnen-Dechent W and Huynh-Do U (2022) Tissue chaperoning—the expanded functions of fetuin-A beyond inhibition of systemic calcification, Pflügers Archiv - European Journal of Physiology, 10.1007/s00424-022-02688-6, 474:8, (949-962), Online publication date: 1-Aug-2022. Matusik P, Łoboda P, Krzanowska K, Popiela T, Heba G and Pawlik W (2020) Presence of retained calcified fibrin sheath after central venous catheter removal: A systematic literature review, The Journal of Vascular Access, 10.1177/1129729820969328, 23:4, (644-652), Online publication date: 1-Jul-2022. Castanheiro Esteves Carias E, Calças Marques R and Paula Andrade da Silva A (2022) Vascular Calcification and Cardiovascular Risk in Chronic Kidney Disease: A Problem That Is Here to Stay Risk Factors for Cardiovascular Disease, 10.5772/intechopen.99886 Waqanivavalagi S, Ground M, Alarcon C, Milsom P and Cornish J (2022) Subcutaneous surgical rat models for the evaluation of decellularised heart valve immunogenicity: A systematic review, Materialia, 10.1016/j.mtla.2021.101298, 21, (101298), Online publication date: 1-Mar-2022. Gimnich O, Zil-E-Ali A and Brunner G (2022) Imaging Approaches to the Diagnosis of Vascular Diseases, Current Atherosclerosis Reports, 10.1007/s11883-022-00988-x, 24:2, (85-96), Online publication date: 1-Feb-2022. Vellanki N, Katsadouros V and Albaghdadi M (2022) Calcified lesions: the interplay between imaging, revascularization effects, role of select debulking technologies and related outcomes Debulking in Cardiovascular Interventions and Revascularization Strategies, 10.1016/B978-0-12-821451-0.00022-7, (321-339), . Whitney K, Dornan G, King J, Chahla J, Evans T, Philippon M, LaPrade R and Huard J (2021) The Effect of a Single Freeze–Thaw Cycle on Matrix Metalloproteinases in Different Human Platelet-Rich Plasma Formulations, Biomedicines, 10.3390/biomedicines9101403, 9:10, (1403) Martínez-Ceballos M, Sinning Rey J, Alzate- Granados J, Mendoza-Pinto C, García-Carrasco M, Montes-Zabala L, Vargas-Vergara D, Munguia-Realpozo P, Etchegaray-Morales I and Rojas-Villarraga A (2021) Coronary calcium in autoimmune diseases: A systematic literature review and meta-analysis, Atherosclerosis, 10.1016/j.atherosclerosis.2021.09.017, 335, (68-76), Online publication date: 1-Oct-2021. Nakahara T, Narula J, Fox J, Jinzaki M and Strauss H (2019) Temporal relationship between 18F-sodium fluoride uptake in the abdominal aorta and evolution of CT-verified vascular calcification, Journal of Nuclear Cardiology, 10.1007/s12350-019-01934-2, 28:5, (1936-1945), Online publication date: 1-Oct-2021. Piri R, Lici G, Riyahimanesh P, Gerke O, Alavi A and Høilund-Carlsen P (2021) Two-year change in 18F-sodium fluoride uptake in major arteries of healthy subjects and angina pectoris patients, The International Journal of Cardiovascular Imaging, 10.1007/s10554-021-02263-7, 37:10, (3115-3126), Online publication date: 1-Oct-2021. Kothari C, Clemenceau A, Ouellette G, Ennour-Idrissi K, Michaud A, Diorio C and Durocher F (2021) Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?, Cancers, 10.3390/cancers13071726, 13:7, (1726) Gonzalez-Galofre Z, Alcaide-Corral C and Tavares A (2021) Effects of administration route on uptake kinetics of 18F-sodium fluoride positron emission tomography in mice, Scientific Reports, 10.1038/s41598-021-85073-0, 11:1 Kim H, Kim C, Cho J, Soeda T, Kurihara O, Russo M, Araki M, Lee H, Minami Y and Jang I (2020) Characteristics of non‐culprit plaques in acute coronary syndrome patients with calcified plaque at the culprit lesion, Catheterization and Cardiovascular Interventions, 10.1002/ccd.29005, 97:3, Online publication date: 15-Feb-2021. Tuzcu Ş, Çetin F, Pekkolay Z, Gezici A and Tuzcu A (2021) Increased Arterial PET/CT 18F-Fluorodeoxyglucose Uptake in Obese and Overweight Patients, Médecine Nucléaire, 10.1016/j.mednuc.2020.03.001, 45:1, (19-26), Online publication date: 1-Feb-2021. Bonfiglio R, Granaglia A, Giocondo R, Scimeca M and Bonanno E (2020) Molecular Aspects and Prognostic Significance of Microcalcifications in Human Pathology: A Narrative Review, International Journal of Molecular Sciences, 10.3390/ijms22010120, 22:1, (120) Omarjee L, Mention P, Janin A, Kauffenstein G, Le Pabic E, Meilhac O, Blanchard S, Navasiolava N, Leftheriotis G, Couturier O, Jeannin P, Lacoeuille F and Martin L (2020) Assessment of Inflammation and Calcification in Pseudoxanthoma Elasticum Arteries and Skin with 18F-FluroDeoxyGlucose and 18F-Sodium Fluoride Positron Emission Tomography/Computed Tomography Imaging: The GOCAPXE Trial, Journal of Clinical Medicine, 10.3390/jcm9113448, 9:11, (3448) Vlasschaert C, Goss C, Pilkey N, McKeown S and Holden R (2020) Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials, Nutrients, 10.3390/nu12102909, 12:10, (2909) Tanoren B, Ugurlucan M and Ates Alkan F (2020) Analysis of atherosclerosis by inductively coupled plasma optical emission spectroscopy and scanning acoustic microscopy, Biomedical Physics & Engineering Express, 10.1088/2057-1976/ab8e96, 6:4, (045004) Dominguez-Gutierrez P, Kwenda E, Khan S and Canales B (2020) Immunotherapy for stone disease, Current Opinion in Urology, 10.1097/MOU.0000000000000729, 30:2, (183-189), Online publication date: 1-Mar-2020. Schantl A, Verhulst A, Neven E, Behets G, D'Haese P, Maillard M, Mordasini D, Phan O, Burnier M, Spaggiari D, Decosterd L, MacAskill M, Alcaide-Corral C, Tavares A, Newby D, Beindl V, Maj R, Labarre A, Hegde C, Castagner B, Ivarsson M and Leroux J (2020) Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers, Nature Communications, 10.1038/s41467-019-14091-4, 11:1 Phadwal K, Feng D, Zhu D and MacRae V (2020) Autophagy as a novel therapeutic target in vascular calcification, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2019.107430, 206, (107430), Online publication date: 1-Feb-2020. Tanoren Bilen B (2020) Designating Vulnerability of Atherosclerotic Plaques Lipid Peroxidation Research, 10.5772/intechopen.90664 Ryoo H, Paeng J, Koo B, Cheon G, Lee D and Kang K (2020) Clinical implication of 18F-NaF PET/computed tomography indexes of aortic calcification in coronary artery disease patients, Nuclear Medicine Communications, 10.1097/MNM.0000000000001115, 41:1, (58-64), Online publication date: 1-Jan-2020. Thankam F, Radwan M and Agrawal D (2020) Inflammation and Epicardial Adipose Tissue in the Pathobiology of Atherogenesis and Neointimal Hyperplasia Following Coronary Intervention Biochemistry of Cardiovascular Dysfunction in Obesity, 10.1007/978-3-030-47336-5_13, (235-266), . Sun H, Zhang F, Xu Y, Sun S, Wang H, Du Q, Gu C, Black S, Han Y and Tang H (2019) Salusin-β Promotes Vascular Calcification via Nicotinamide Adenine Dinucleotide Phosphate/Reactive Oxygen Species-Mediated Klotho Downregulation , Antioxidants & Redox Signaling, 10.1089/ars.2019.7723, 31:18, (1352-1370), Online publication date: 20-Dec-2019. Harman J and Jørgensen H (2019) The role of smooth muscle cells in plaque stability: Therapeutic targeting potential, British J